Author of

• 28323

  +

  19 - Debate #3 Optimal Therapy After Progression on Osimertinib with No New Driver is Chemotherapy Alone (ID 19)

  • Event: TTLC 2019
  • Type: General Session
  • Track:
  • Presentations: 1
  • Moderators:Ravi Salgia
  • Coordinates: 2/22/2019, 18:05 - 18:20, Starlight Ballroom

  • 28503

    +

    Yes - Chemo Alone (ID 19.02)

    18:05 - 18:20  |  Author(s): Frances Shepherd
    • Abstract
    • Slides

    Abstract not provided

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.